China's Venus Medtech completes first VenusP-Valve implantation in US's PROTEUS IDE Pivotal Clinical Study.
China's Venus Medtech, a leading provider of transcatheter structural heart valvular therapies, has completed the first implantation of its in-house developed VenusP-Valve in the US's PROTEUS IDE Pivotal Clinical Study. The procedure took place at the University of Virginia School of Medicine under the guidance of Prof. Scott Lim and Prof. Michael Hainstock. The VenusP-Valve, approved for CE MDR in April 2022, marks a significant milestone in its international progress.
June 14, 2024
5 Articles